Q2 FY2026 · ended Jun 30, 2026 · Revenue $0, -100.0% YoY · Filed Aug 11, 2026
Taysha Gene Therapies, Inc. (TSHA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $46.6 million. Free cash flow was -$40.4 million. As of Jun 30, 2026 it held $455.4 million in cash and investments and $56.7 million in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TSHA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Dallas, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1806310
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $5.5M | $0 | $2.0M |
| Operating income | -$47.3M | -$43.5M | -$28.3M | -$34.0M | -$26.8M |
| Net income | -$46.6M | -$42.4M | -$27.9M | -$32.7M | -$26.9M |
| Diluted EPS | -$0.13 | -$0.12 | -$0.08 | -$0.09 | -$0.09 |
| Operating cash flow | -$40.4M | -$40.9M | -$26.7M | -$24.2M | -$20.2M |
| Free cash flow | -$40.4M | -$40.9M | -$27.0M | -$24.3M | -$20.6M |
| Total assets | $470.4M | $300.4M | $343.3M | $316.6M | $333.3M |
| Total liabilities | $83.2M | $88.4M | $96.4M | $97.6M | $84.6M |
| Stockholders' equity | $387.3M | $211.9M | $246.9M | $219.0M | $248.7M |
| Cash and investments | $455.4M | $276.6M | $319.8M | $297.3M | $312.8M |
| Total debt | $56.7M | $68.6M | $70.1M | $69.1M | $59.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 25, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 22, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 2, 2026 | Jun 1, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
All 401 Taysha Gene Therapies, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.